COIOSDeep risk insights through multi-disciplinary research across the globe
A small village nestled in rolling, dry hills
Item new Preprint · not peer-reviewed Added

Myelosuppression is gemcitabine's most consistent signal in FDA adverse event reports

In 18.37 million adverse event reports made to the FDA since 2014, myelosuppression was reported 3.35 to 7.74 times more often with gemcitabine regimens than with other drugs.

The authors compared how often harms were reported with gemcitabine against all other drugs in 18.37 million FDA reports from 2014 to 2026. Myelosuppression was reported 3.35 to 7.74 times more often than expected, whether gemcitabine was given alone or in combination. A liver toxicity signal of 10.32 for three-drug regimens fell to 1.62 when only reports naming gemcitabine as the suspected cause were counted.

Why it is interesting: How far a reporting signal moves once the counting rule changes, for a first-line cancer regimen.

Source
medRxiv, 27 September 2026
Paper
Reporting Odds Ratio Analysis of Gemcitabine-Based Chemotherapy Regimens for Biliary and Pancreatic Cancer: Population-Level Toxicity Signals and Hypotheses for High-Altitude Generalizability
Authors
Dang Z, Dan J, Li S, Yanan L, Su W, Ren G et al.
DOI
10.64898/2026.09.24.26363686
Type
Preprint
Design
Disproportionality analysis (ROR, PRR, IC, EBGM) of FAERS spontaneous reports, 2014-2026, 18.37M reports
Verdict
New finding
Driver
Cancer

Other drivers in Health today